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Microbial drug-resistance demands immediate implementation of novel 25 
therapeutic strategies. Antimicrobial photodynamic therapy (aPDT) combines 26 
the administration of a photosensitizer (PS) compound with low-irradiance light 27 
to induce photochemical reactions that yield reactive oxygen species (ROS). 28 
Since ROS react with nearly all biomolecules, aPDT offers a powerful 29 
multitarget method to avoid selection of drug-resistant strains. In this study, we 30 
assayed photodynamic inactivation under a standardized method, combining 31 
methylene blue (MB) as PS and red light, against global priority pathogens. The 32 
species tested include Acinetobacter baumannii, Klebsiella aerogenes, 33 
Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 34 
Enterococcus faecium, Enterococcus faecalis, Staphylococcus aureus, 35 
Candida albicans and Cryptococcus neoformans. Our strain collection presents 36 
resistance to all tested antimicrobials (>50). All drug-resistant strains were 37 
compared to their drug-sensitive counterparts. Regardless of resistance 38 
phenotype, MB-aPDT presented species-specific dose-response kinetics. 39 
More than 5log10 reduction was observed within less than 75 seconds of 40 
illumination for A. baumannii, E. coli, E. faecium, E. faecalis and S. aureus and 41 
within less than 7 minutes for K. aerogenes, K. pneumoniae, P. aeruginosa, C. 42 
albicans and C. neoformans. No signs of cross-resistance or -tolerance in 43 
between aPDT and standard chemotherapy was observed. Therefore, MB-44 
aPDT can provide effective therapeutic protocols for a very broad spectrum of 45 
pathogens. Hence, we believe that this study represents a very important step 46 
to bring aPDT closer to implementation into mainstream medical practices. 47 
Keywords: Drug resistance; ESKAPE; Multidrug resistance; Photoinactivation.   48 
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1. Introduction 49 
The global crisis of antimicrobial resistance (AMR) is now accepted both 50 
by the research community and health authorities [1–4]. The lack of effective 51 
agents could mean the end of modern medicine worldwide, with simple 52 
infections again associated with high mortality rates and even routine surgical 53 
procedures becoming unsafe [4]. Access to effective conventional therapeutics 54 
is also becoming more difficult due to an insufficient pipeline of new drugs [5]. 55 
Among bacterial infections, resistance may – of course – be 56 
encountered anywhere, but the leading cause of nosocomial infections globally 57 
is the ESKAPE group. The members of this group are commonly associated 58 
with multidrug-resistance and can thus circumvent the effects of a number of 59 
different classes of conventional antibacterial agents [6,7]. Consequently, some 60 
illnesses caused by these bacteria are very challenging to treat with the current 61 
armamentarium. 62 
 Such is the gravity of the situation that governments, healthcare 63 
providers and the pharmaceutical industry now recognize the requirement for 64 
non-conventional therapeutic approaches to combat AMR [4,8]. However, such 65 
alternatives must be robust, reliable and offer antimicrobial coverage exceeding 66 
that of conventional agents, particularly with respect to resistance. Biologicals 67 
such as vaccines and phage therapy are among alternatives proposed, but 68 
clearly both of these are highly specific in terms of the target rather than 69 
representing generally useful antimicrobial approaches with non-conventional 70 
routes to target toxicity. 71 
Antimicrobial photodynamic therapy (aPDT) is an interesting method to 72 
produce cytotoxic molecular species in a space-time-controlled manner. This 73 
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light-based technology platform uses low-to-mid irradiance (i.e., non-thermal) 74 
light in combination with a non-toxic compound, termed photosensitizer (PS), 75 
to treat localized infections [9,10]. Therefore, microbial inactivation mediated by 76 
photodynamic reactions may only occur where the photosensitizer is present 77 
and when it is being activated by light. The light-excited photosensitizer (3PS*) 78 
interacts with a biological substrate or molecular oxygen (O2), either by charge 79 
or energy donation, producing a variety of reactive oxygen species (ROS) and 80 
radical reactions [11,12]. Products such as singlet oxygen or hydroxyl radicals 81 
are so reactive that in sufficient amounts, they can destroy any type of microbial 82 
cell regardless of taxonomy. Hence, this non-conventional mode of action 83 
provides effective kill regardless of conventional drug-resistance mechanisms 84 
[10,13–17].  85 
In this study, we assayed the photodynamic antimicrobial efficiency of a 86 
broadly available photosensitizer drug (methylene blue, MB) and red light 87 
against bacterial and fungal species frequently associated with drug-resistance. 88 
We tested bacteria resistant to nearly all antibacterial drugs (>50), including the 89 
entire ESKAPE group [1], WHO global priority pathogens [5,18] and azole-90 
resistant fungi, to compare them to standard control strains. The study is 91 
therefore highly relevant in providing an examination of the efficacy of the 92 
photodynamic approach with a single agent against multiple, different microbial 93 
resistance mechanisms. 94 
 95 
2. Material and Methods 96 
 97 
2.1. Strains and inocula preparation 98 
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We used a collection of 23 strains from 8 bacterial species (E. faecium, 99 
E. faecalis, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, K. 100 
aerogenes and E. coli), as well as 4 strains from 2 yeast species (C. albicans 101 
and C. neoformans).  102 
All bacterial strains were first subcultured from frozen vial stocks onto 103 
Muller-Hinton agar for 24 h at 37º C. Yeast were subcultured onto Sabouraud 104 
dextrose agar under the same procedure. Individual colonies were then seeded 105 
into Muller-Hinton or Sabouraud dextrose broth and incubated overnight under 106 
shaking regimen (115 rpm) at 37°C. 107 
 108 
2.2. Qualitative antimicrobial-resistance profile 109 
Qualitative susceptibility assay was performed by Kirby-Bauer disk-110 
diffusion method with interpretative criteria based on CLSI 2017 111 
recommendations of inhibition diameter breakpoints [19]. We assayed a total 112 
of 43 representative antimicrobials against Gram-negative and 35 against 113 
Gram-positive bacteria. Minimum inhibitory concentration (MIC) assays were 114 
performed, as recommended by CLSI 2017, to determine the vancomycin-115 
intermediate resistance of S. aureus, colistin resistance of E. coli and 116 
fluconazole resistance of fungi.  117 
 118 
2.3. Photosensitizer and light source 119 
We used the phenothiazine salt methylene blue hydrate (MB, purity > 120 
95%, Sigma-Aldrich) as a representative PS compound. Stock solutions of MB 121 
were prepared in type-1 Milli-Q water, at 10 mM. All MB stock solutions were 122 
filtered by 0.22 µm membrane for microbial decontamination, aliquoted into 123 
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Eppendorf tubes and stored in the dark before use. MB working concentration 124 
was set at 100 µM in PBS. All experiments were performed with 1 mL of MB-125 
inocula solution in wells of a 12-well cell culture plate (length of the optical path 126 
in solution was 2 mm). 127 
We used a prototype LED system (660 +/- 10 nm, LEDsaber Prototype 128 
1, BioLambda, Brazil) that was previously characterized by an UV-VIS 129 
spectrophotometer (Flame, Ocean Optics, USA). Light irradiance was adjusted 130 
to a standard irradiance of 100 mW/cm2 measured at the sample bottom. Beam 131 
spot diameter was the same as a well of the 12-well plate (i.e., 25 mm), with 132 
maximum irradiance variation between center and border below 10%. 133 
 134 
2.4. aPDT studies for planktonic suspensions   135 
We performed standard aPDT susceptibility tests based on the study 136 
published by Sabino et al. [20]. Inocula were prepared from overnight broth 137 
cultures under shaking regimen. Inocula concentrations were adjusted to obtain 138 
OD of 0.09 at 540 nm and 625 nm resulting in 1-2 x 106 CFU/mL of fungal cells 139 
and 1-2 x 108 CFU/mL of bacterial cells, respectively. Inocula were then diluted 140 
to a working concentration of 1-2 x 105 CFU/mL of fungi or 1-2 x 107 CFU/mL 141 
of bacteria.  142 
Before irradiation, cells were incubated with MB in phosphate-buffered 143 
saline (PBS) for 10 min at room temperature and in the dark, to allow initial 144 
cellular uptake. To avoid cross light exposure, 1 mL of each sample was placed 145 
in the 12-well plate only for irradiation procedure. Three types of controls were 146 
used for all experiments: non-treated cells (PBS only), light alone (highest light 147 
7 
 
dose without MB exposure) and MB alone (MB exposure without light during 148 
the entire experimental period). 149 
Experimental procedure for irradiation was performed with variable 150 
radiant exposure. Radiant exposure levels were varied according to each 151 
microbial species sensitivity MB-aPDT as previously determined in pilot 152 
experiments. Basically, species were divided into 2 radiant exposure ranges: 153 
1 J/cm2 steps (A. baumannii, E. faecalis, E. faecium, E. coli and S. aureus) or 154 
5 J/cm2 steps (K. aerogenes, K. pneumoniae, P. aeruginosa, C. albicans and 155 
C. neoformans). Radiant exposure was calculated as the product of irradiance 156 
(W/cm2) and the exposure time (seconds). 157 
Following irradiation procedures, each bacterial suspension was serially 158 
diluted in PBS and 10 µL aliquots of each dilution were seeded onto Muller-159 
Hinton (bacteria) or Sabouraud dextrose (yeast) agar plates in triplicate and 160 
incubated at 37° C overnight. On the next day, colonies were counted and 161 
converted into normalized log10 units of CFU/mL for survival fraction analysis. 162 
  163 
2.5. Statistical analysis 164 
All data were obtained from at least three independent experiments, 165 
each performed in triplicate, resulting in a minimum of nine samples per group. 166 
Quantitative data are presented as log10 of normalized means and standard 167 
deviation of means.  168 
All inactivation kinetics data were fitted by power-law (eq. 1) for statistical 169 
comparison of each inactivation kinetics curve according to Sabino et al. [20]. 170 
LD90 and T (tolerance factor) values were initially obtained for each strain by 171 
non-linear regression analysis. Then the same analysis was performed for the 172 
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average inactivation kinetics of each species. Using the average inactivation 173 
kinetics of each species, we also calculated the LD99.9, LD99.999 using equation 174 

















 Equation 2 
where: 176 
N0= initial microbial burden; N= final microbial burden; Dose= light 177 
exposure (e.g. J, J/cm2, time units, Absorbed Photons/cm3, etc.); LD90= lethal 178 
dose for 90% of microbial burden (in light exposure units); T= tolerance factor; 179 
i= inactivation percentage (%). 180 
 181 
Statistical differences of all LD90, LD99.9, LD99.999 and T values were then 182 
compared in between strains and species using one-way ANOVA with Tukey 183 
as post-test. Statistical results were considered significant if p < 0.05 and are 184 
presented in the supplementary information section.  185 
 186 
3. Results 187 
Antimicrobial susceptibility profiles of all strains are presented in 188 
supplementary tables S1-3. The inhibition diameters of unclassified 189 
antimicrobials are presented in numeric values (mm). For all species, we had 190 
one drug-sensitive strain and at least one multidrug-resistant (MDR) and/or 191 
extensively drug-resistant (XDR) representative strain [21]. Thus, we used ten 192 
drug-sensitive controls (S. aureus ATCC 29923; E. faecium ATCC BAA2127; 193 
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E. faecalis ATCC 29212; P. aeruginosa ATCC 27853; A. baumannii ATCC 194 
19606; K. aerogenes ATCC 13048; E. coli ATCC 25922; K. pneumoniae ATCC 195 
700603; C. albicans ATCC 90028; C. neoformans KN99a), thirteen MDR (S. 196 
aureus VRSA-BR-4; E. faecium ATCC 700221; E. faecalis ATCC 51299; K. 197 
pneumoniae KP-BR-1, 11978, ATCC BAA1705; A. baumannii 804, LDC; K. 198 
aerogenes E0083033-1; E. coli 19B, ICBEC7P; C. albicans IAL2151; C. 199 
neoformans H99) and four XDR strains (K. pneumoniae KP148/PINH-4900; P. 200 
aeruginosa 1997A-48, PA64, ICBDVIM2). In a general perspective, resistance 201 
to all tested antibiotics except for linezolid was detected (tables S1-3). 202 
Fluconazole resistance was confirmed for C. albicans (IAL2151) and C. 203 
neoformans (H99). 204 
A remarkable fact that can be extracted from our data (figure 1-2) is that 205 
microbial inactivation kinetics induced by MB-aPDT do not seem to depend on 206 
the conventional drug-resistance profile of different strains. At least for the 207 
representative MDR and XDR strains tested, current drug-resistance does not 208 
impose any further challenges for MB-aPDT. For all tested strains, LD90 and T 209 
values did not show any statistically significant differences within the same 210 
species. On the other hand, inactivation kinetics present great variations among 211 
different species of bacteria and yeast.  212 
Regardless of taxonomy, all strains presented >5log10 of burden 213 
reduction for radiant exposures greater than 40 J/cm2 (figure 1-2). However, 214 
C. albicans, C. neoformans, K. pneumoniae, K. aerogenes and P. aeruginosa 215 
presented a distinguishable tolerance to MB-aPDT. Light-doses required to 216 
inactivate 99.999% of these species were 2 to 10 times higher when compared 217 
to A. baumannii, E. coli, E. faecalis, E. faecium and S. aureus. However, it 218 
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should be noted that this would not be problematic from a clinical viewpoint, 219 
since 40 J/cm2 of irradiation at 100 mW/cm2 (same irradiance as used in this 220 
study) would correspond to less than a 7-minute procedure. 221 
The microbial diversity assayed by this study in a standard manner 222 
allows us to observe some situations that diverge from some current thinking 223 
in the aPDT field. Based on our results, the classic generalization that aPDT 224 
sensitivity increases in the order fungi < Gram-negative < Gram-positive is no 225 
longer sustained [22]. The Gram-positives E. faecalis and E. faecium, for 226 
example, tend to be more tolerant to aPDT than Gram-negative species, such 227 
as E. coli and A. baumannii. Even though, S. aureus, E. coli, A. baumannii, E. 228 
faecalis and E. faecium do not present statistically significant differences for 229 
LD90, LD99.9 and LD99.999 (supplementary table S4). In addition, the bacterium 230 
K. pneumoniae is slightly more tolerant than the C. neoformans yeast, but with 231 
no statistical significance. For LD99.999, C. neoformans does not present 232 
statistically significant differences with the bacteria K. aerogenes and P. 233 
aeruginosa. The most tolerant species to MB-aPDT was C. albicans. It does 234 
not present statistically significant differences with K. pneumoniae at LD90.  235 
However, it was significantly more tolerant than all other species at LD99.9 and 236 
LD99.999. 237 
Non-linear regression results for strain averages of each species are 238 
respectively presented in figures 3 and 4 as values of the tolerance factor (T), 239 
and lethal dose for 90% of inactivation (LD90). The tolerance factor T (figure 3, 240 
statistical analysis in supplementary table S5) informs the concavity of the 241 
inactivation curves; if T>1, the microbial population is initially tolerant to aPDT 242 
but becomes increasingly sensitive; if T<1, the microbial population is initially 243 
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sensitive, but some persistent cells remain more tolerant to inactivation as 244 
irradiation progresses. If T=1, the microbial population presents a constant 245 
inactivation kinetics rate. These characteristics are clearly observable in 246 
figures 1 and 2, where K. pneumoniae, P. aeruginosa, E. faecium, E. faecalis 247 
and yeast presented T factors equal or greater than 1. Regarding E. faecalis, 248 
an interesting feature is highlighted by the use of non-linear regressions: by the 249 
beginning of irradiation process this species is more tolerant than E. coli, S. 250 
aureus and A. baumannii. However, due to the concavity of its inactivation 251 
kinetics curve (i.e., T~1), at LD99.999 it becomes the most sensitive species to 252 
MB-aPDT (not statistically significant for S. aureus, A. baumannii, E. coli and 253 
E. faecium, supplementary table S4). 254 
 Regarding lethal doses, an interesting behavior occurs: LD90 values 255 
present variations greater than 2 orders of magnitude amongst different 256 
species, such as the extreme case of S. aureus and K. pneumoniae, even 257 
though, due to variations in T values, all species seem to converge to closer 258 
LD99.9 and LD99.999 values (figure 4). Species with T>1 tend to present higher 259 
LD90; for those with T<1 the opposite behavior is observed. Regarding the 260 
example of S. aureus and K. pneumoniae again, LD99.999 variation is reduced 261 
to less than one order of magnitude.  262 
 263 
4. Discussion 264 
 Here we used drug-resistant phenotypes for all tested commercial 265 
antimicrobials (>50), with a single exception for linezolid. If such drug-266 
resistance profiles are detected in clinical cases, prognostics can hardly be 267 
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optimistic. Consequently, cost and risk management of pathogens 268 
significantly increases.  269 
 Costs associated with drug-resistant infections could be significantly 270 
reduced if health insurance companies and public hospitals offered aPDT as 271 
an option. Light sources can be reused countless times and PS doses of most 272 
commercially available dyes are relatively inexpensive. In our example, a one-273 
mL dose of MB at 100 µM costs fractions of US-dollar cents and can be 274 
purchased in most pharmacies as a standard drug to treat methemoglobinemia 275 
or carbon monoxide poisoning. MB is a particularly interesting photosensitizer 276 
since it is cost-effective, safe, globally available and has been proved effective 277 
for several clinical applications of aPDT [10,13,23,24]. MB also presents 278 
intense light absorption properties (peak at 664nm) in the optical window of light 279 
penetration into biological tissues (i.e., 600-1350 nm) [23,25]. Therefore, in our 280 
perspective, MB has great potential to be the first PS to be employed in 281 
mainstream medical procedures of aPDT applications. 282 
Antimicrobial chemotherapeutic strategies generally target singular 283 
microbial molecules or metabolic pathway stages to achieve specific microbial 284 
inactivation. This approach facilitates the development or selection of resistant 285 
populations as they may be just a mutation away. Most antimicrobials are 286 
derivatives of natural fungal or bacterial metabolites that have been used by 287 
them to gain privileges over ecosystems. In this context, some microorganisms 288 
have naturally developed a resistance phenotype to also thrive in the 289 
environment.  290 
Currently, hospital, farm and domestic effluents represent important 291 
environments that carry and gather resistance genes. Carbapenemases are 292 
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being frequently detected in plasmids of Gram-negative clinical isolates of the 293 
Enterobacteriaceae family and non-fermenters such as P. aeruginosa and A. 294 
baumannii [26,27]. The genetic versatility of the Enterobacteriaceae is 295 
considered responsible for the global dissemination of KPC and has most likely 296 
enabled processes of adaptation and virulence expression in different 297 
ecosystems [28]. More worrisomely, the recent identification of the plasmid-298 
mediated mcr-1 gene, which confers resistance to polymyxins – a last-resort 299 
drug to treat carbapenem-resistant Gram-negative infections – has added 300 
another layer of complexity to therapeutic strategies for nosocomial infections.  301 
Antimicrobial photodynamic therapy offers an effective strategy to 302 
challenge microbial resistance in local infections as it differs from traditional 303 
chemotherapy in one important point: it lacks molecular target specificity. Unlike 304 
traditional antimicrobial therapy, aPDT imposes its cytotoxic effects by high 305 
yields of ROS generation. ROS do not target a particular pathway but rather 306 
destroy proteins, nucleic acids and lipids indiscriminately. Due to their broad 307 
reactivity range, the biological target of photodynamically-produced ROS will 308 
mostly depend on the cell/tissue compartment in which it was produced (i.e., 309 
where the PS accumulates) [29]. Given that in our system each MB molecule 310 
can theoretically produce more than 105 singlet oxygen molecules per second, 311 
microorganisms simply seem to not be equipped with enough antioxidant 312 
capacity to tolerate an attack of this magnitude [30]. Additionally, at low MB-313 
aPDT doses (i.e. doses that are insufficient to present microbicidal effects), the 314 
exposed pathogens remain with transiently inhibited virulence factors, including 315 
increased antimicrobial sensitivity [31–34]. We previously reported that low-316 
doses of systemic aPDT could temporarily inhibit the drug-resistance 317 
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phenotype of vancomycin-resistant E. faecium and fluconazole-resistant C. 318 
albicans [31,32]. Therefore, the combination of aPDT with antimicrobial agents 319 
can potentially present synergistic activity or temporarily return drug-sensitivity. 320 
Furthermore, in combination with the innate immune system it may yet trigger 321 
responses that can lead to resolution of the infection [35]. 322 
In the related anticancer application, which uses different PS classes, 323 
mechanisms of resistance to PDT have already been reported [36]. A classic 324 
example is the constant failure to treat melanoma tumors [37]. Melanin is an 325 
antioxidant cellular defense and simultaneously blocks light propagation due to 326 
intense filter effect [38,39]. Drug sequestration in melanosomes has also been 327 
implicated with photosensitizers, as in cases of chemoresistance [40,41]. 328 
Similarly, melanization of C. neoformans yeast also increases its tolerance to 329 
photodynamic inactivation as seen in antifungal chemotherapy and upon 330 
gamma irradiation [34,42–44]. In a broader view, several microbial pigments 331 
can act as potent antioxidant defenses against environmental harms and as an 332 
immune system evasion strategy. Mycobacteria, staphylococci, 333 
chromobacteria and cryptococci can produce fair amounts of carotenoids and 334 
tryptophan-derived pigments to guarantee superior oxidative tolerance through 335 
ROS quenching [45]. However, it is well known by the aPDT community, and 336 
was further confirmed in our study, that the carotenoid-producing S. aureus is 337 
one of the most sensitive microorganisms to photo-oxidative inactivation with 338 
amphiphilic photosensitizers. Currently, it has not been established whether 339 
aPDT could lead to the selection for oxidative tolerant strains that overexpress 340 
pigment-producing enzymes and impair the technique effectiveness. Perhaps 341 
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the most tolerant microbial species used in this study are protected by potent 342 
antioxidant defense systems.  343 
Overexpression of ATP-binding cassette (ABC) transporters has been 344 
implicated as another resistance mechanism to aPDT [46]. Tumor and 345 
microbial cells can use this mechanism to tolerate chemotherapy and PDT [47–346 
49]. ABC-transporters, as P-glycoprotein, are efficient efflux pumps that can 347 
inhibit the uptake of multiple drugs and PS that function inside the cell. To avoid 348 
or overcome this resistance mechanism, efflux pump inhibitors or PSs that 349 
function on the cell surface may be used [50–52]. Trindade et al. reported that 350 
MB was able to revert multidrug-resistance phenotypes of cancer cells via 351 
oxidation of efflux-pumps [53]. This suggests that synergistic activity between 352 
MB-aPDT and fluconazole, on azole-resistant C. albicans, may share the same 353 
mechanism [31,54].  354 
Trindade et al. also reported that the MDR phenotype of cancer cells, 355 
mediated by efflux-pumps, does not impose any further challenge for MB-PDT 356 
inactivation [53]. As in our experiments, their results suggest that cellular 357 
sensitivity to MB-PDT are rather dependent on the species than the MDR 358 
phenotype. Here we used drug-resistant representatives for nearly all classes 359 
of antimicrobials. Resistance mechanisms to quinolones, phenicols, 360 
tetracyclines, aminoglycosides and fluconazole are highly associated with 361 
overexpression of drug-efflux pumps. Even though MB may also be a substrate 362 
of efflux proteins, no relevant differences between drug-sensitive and resistant 363 
strains could be observed.  364 
In the microbiology community, a microbial strain is considered resistant 365 
to a certain antimicrobial if its MIC cannot be reached safely in patient’s 366 
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bloodstream via oral or intravenous administration. Therefore, a drug-resistant 367 
microorganism is untreatable by the use of certain systemically administered 368 
chemotherapeutic antimicrobials. Since aPDT is never systemically 369 
administered there is no influence on antimicrobial drug concentration in the 370 
bloodstream. Additionally, light dosimetry can always be increased to enhance 371 
aPDT microbicidal activity. On the other hand, tolerance is used as a relative 372 
term that describes a higher demand of light or photosensitizer dosimetry to 373 
reach a certain level of microbial inactivation. Hence, higher tolerance to aPDT 374 
does not mean that the effective dose cannot be reached. In regard to the 375 
tolerance factor (T) we use to describe inactivation kinetics, it only informs if 376 
some specific species is more tolerant to inactivation in the beginning or the 377 
end of a light-mediated microbicidal procedure. 378 
Fungi and capsule-expressing Gram-negative bacteria, however, indeed 379 
present a higher tolerance to aPDT. Prates et al. demonstrated that capsule 380 
deletion in C. neoformans guarantees greater sensitivity to aPDT mediated by 381 
cationic PS, including MB [34]. Therefore, we hypothesized that the capsule 382 
barrier could protect microorganisms from aPDT, possibly reducing MB 383 
incorporation into the cytoplasm. A carbohydrate-rich capsule may act as a 384 
negatively charged electrostatic pool, diminishing intracellular incorporation of 385 
MB; or it may act by simply increasing cellular biomass, bringing further targets 386 
for nonspecific photodynamic damage in non-vital structures. For fungi, 387 
however, a capsule does not seem to be as important as for bacteria. Even 388 
though it was demonstrated that capsule deletion in C. neoformans enhanced 389 
its sensitivity to aPDT, C. albicans does not produce a capsule and is more 390 
tolerant to aPDT than C. neoformans. We do not provide sufficient data to 391 
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elucidate this finding, so we can only hypothesize that C. albicans may have 392 
cytosolic, mitochondrial and nuclear ROS defense that is less prevalent in C. 393 
neoformans [55,56]. 394 
Although our data seems to suggest that capsule expression in bacterial 395 
results in higher aPDT tolerance, capsule presence in yeasts does not seem to 396 
increase aPDT tolerance. Capsule presence has been implicated as a relevant 397 
tolerance factor to aPDT, especially in the case of C. neoformans [34]. 398 
However, our data suggest that there must be other more relevant tolerance 399 
factors expressed by different species. Greater MB-aPDT tolerance may be 400 
rather related to cellular antioxidant systems, organelle compartmentalization 401 
and/or capacity to pump photosensitizers out of the cell through efflux systems 402 
[46]. 403 
Photosensitizers that preferentially undergo type I photodynamic 404 
reactions are more susceptible to microbial antioxidant defense since there are 405 
specific detoxifying enzymes for the photoproducts formed. Constitutive 406 
overexpression of superoxide dismutase, catalase, peroxiredoxin and 407 
glutathiones, or the accumulation of manganese ions can represent effective 408 
protection against oxidation by superoxide and hydroxyl radicals [57–59]. All of 409 
the mentioned features can be sufficient to impose challenges for PDT to treat 410 
tumors and microorganisms resistant to traditional chemotherapy and 411 
radiotherapy. However, since no enzymes capable of inactivating singlet 412 
oxygen efficiently have ever been reported, and since, in our hands, complete 413 
microbial inactivation required only around 7 minutes for the most tolerant 414 
species, it remains questionable whether any type of resistance to aPDT could 415 
ever be developed.  416 
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Here, we demonstrated that regardless of taxonomy or drug-resistance 417 
profile, all strains among each species are similarly sensitive to aPDT. Our 418 
results consequently support the proposition of aPDT as a consistent challenge 419 
against drug-resistance in local infections. MB-aPDT effects against these 420 
species have indeed been published elsewhere [10,16,24,60]. However, there 421 
was never a study performed with all of them being inactivated under 422 
standardized experimental parameters. It is widely known that the aPDT 423 
community lacks on standards for in vitro aPDT assays and that any changes 424 
in inocula concentration, photosensitizer concentration, solvent composition 425 
(e.g., water, PBS, saline solution, etc.), light irradiance, optical path, and other 426 
factors may lead to diverging results [61–63]. Therefore, it is very unlikely that 427 
precise comparisons of inactivation kinetics data are achievable between two 428 
studies performed by different teams who varied any of the above-mentioned 429 
parameters and analyzed a reduced spectrum of species. For example, such 430 
incapacity to compare results from different studies may have led to the 431 
persistently mistaken concept that Gram-positives are more sensitive than 432 
Gram-negatives that are more sensitive than fungi [22]. This mistaken 433 
information has persisted in our community for more than a decade whereas 434 
the current manuscript shows that Gram-positives can be more tolerant than 435 
Gram-negatives, which can also be more tolerant than fungi.  436 
This information could be mistakenly interpreted again if we did not 437 
analyze inactivation kinetics as a curve fit instead of just reading individual data 438 
points.  Hence, our standardized study of a broad spectrum of global priority 439 
pathogens does bring important insights about their sensitivity to MB-aPDT. 440 
Furthermore, we recently published a paper presenting a mathematical model 441 
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of analysis for microbial photoinactivation kinetics. So far, all studies used to 442 
compare inactivation kinetics are based on individual dose points, which is 443 
another issue that could lead to misleading statistical differences that do not 444 
represent the actual inactivation kinetics rate. Because of variable tolerance 445 
factors (T) the comparison of two different species could be misleading 446 
because some data points may not present significant differences, while others 447 
do (see the examples of S. aureus versus E. faecalis at 1 and 3 J/cm2, Figure 448 
1). Because of this, several papers actually show significant differences 449 
between different strains of the same species. Even though many studies show 450 
that drug-resistant strains are also sensitive to aPDT, many of those do not 451 
compare with standard ATCC drug-sensitive controls. When they do, 452 
misleading statistics often show differences between strains because of the 453 
previously mentioned statistical issue of comparing a single dose point. 454 
 455 
5. Conclusion 456 
 In summary, our study unequivocally demonstrates that antimicrobial 457 
photodynamic inactivation offers a powerful strategy to challenge microbial 458 
drug-resistance. For the first time, we compiled a large amount of data under a 459 
standardized method showing that MB-aPDT is effective against 460 
microorganisms that are resistant to more than 50 antimicrobial agents. 461 
Regardless of taxonomy or resistance phenotype, MB-aPDT presented 462 
consistent dose-response kinetics. Therefore, MB-aPDT can provide effective 463 
therapeutic protocols for a very broad spectrum of pathogens. This approach 464 
can be employed to significantly reduce the use of antimicrobial drugs and 465 
minimize the risk of us entering into a post-antimicrobial era. Hence, we believe 466 
20 
 
that this study represents a very important step in bringing aPDT closer to 467 
implementation into mainstream medical practices. 468 
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Figure legends 791 
 792 
Figure 1. Inactivation kinetics of bacterial species most sensitive to MB-aPDT 793 
(scale 1) in function of radiant exposure. Average inactivation kinetics data of 794 
all strains of each species in this board is presented in a. Inactivation kinetics 795 
of each strain is also shown for A. baumannii (b), E. faecalis (c), E. faecium (d), 796 
E. coli (e) and S. aureus (f).  797 
 798 
Figure 2. Inactivation kinetics of bacterial and yeast species most tolerant to 799 
MB-aPDT (scale 5) in function of radiant exposure. Average inactivation 800 
kinetics data of all strains of each species in this board is presented in a. 801 
Inactivation kinetics of each strain is also shown for K. aerogenes (b), K. 802 
pneumoniae (c), P. aeruginosa (d), C. neoformans (e) and C. albicans (f).  803 
 804 
Figure 3. Tolerance factor (T) of inactivation kinetics calculated for each tested 805 
species. If T>1, microbial population is initially tolerant to aPDT but become 806 
increasingly sensitive. If T<1, microbial population is initially sensitive, but some 807 
persistent cells remain more tolerant to inactivation as irradiation progresses. If 808 
T=1, microbial population presents a constant inactivation kinetics rate in a log-809 
scale. 810 
 811 
Figure 4. Lethal dose values of aPDT calculated in function of radiant 812 
exposure. LD values correspond to percent of total microbial population 813 
reduction. Horizontal dotted line represents the maximum dose (40 J/cm2) 814 




Table 1. List of microbial strains used in this study. 817 
Bacterial Species Strain Capsule 
Drug-sensitive control strains 
Acinetobacter baumannii ATCC 19606 – 
Candida albicans ATCC 90028 – 
Cryptococcus neoformans KN99a + 
Klebsiella aerogenes ATCC 13048 + 
Enterococcus faecalis ATCC 29212 – 
Enterococcus faecium ATCC BAA-2127 – 
Escherichia coli ATCC 25922 – 
Klebsiella pneumoniae (ESBL, SHV-18) ATCC 700603 + 
Pseudomonas aeruginosa ATCC 27853 + 
Staphylococcus aureus ATCC 25923 – 
Drug-resistant strains (resistance phenotype) 
Acinetobacter baumannii (carbapenemase OXA-23) LDC [64] – 
Acinetobacter baumannii (carbapenemase OXA-143) 804 [65] – 
Candida albicans (azole resistant) IAL2151 [66] – 
Cryptococcus neoformans (azole resistant) H99 [54] + 
Klebsiella aerogenes (carbapenemase NDM-1) E0083033-1 [67] + 
Enterococcus faecalis (vancomycin-resistant VanB) ATCC 51299 – 
Enterococcus faecium (vancomycin-resistant VanA) ATCC 700221 – 
Escherichia coli (ESBL CTX-M-8) 19B [68] – 
Escherichia coli (ESBL CTX-M-1, colistin-resistant MCR-1) ICBEC7P [69] – 
Klebsiella pneumoniae (metallo-β-lactamase IMP-1, ESBL CTX-M-2) KP BR-1 [70] + 
Klebsiella pneumoniae (carbapenemase KPC-2) ATCC BAA1705 + 
Klebsiella pneumoniae (carbapenemase OXA-48) 11978 [71] + 




Pseudomonas aeruginosa (carbapenemase GES-5) PA64 [73] + 
Pseudomonas aeruginosa (metallo-β-lactamase SPM-1) 1997A-48 [74] + 
Pseudomonas aeruginosa (metallo-β-lactamase VIM-2) ICBDVIM2 [75] + 
Staphylococcus aureus (MRSA, VRSA) VRSA BR-4 [76] – 
 818 
